Outlook Therapeutics, Inc. — Form SCHEDULE 13D/A
Filed August 14, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 28/100
What the filing says
GMS Ventures Investments filed an amended Schedule 13D/A on August 14, 2026, regarding beneficial ownership in Outlook Therapeutics, Inc. (market cap ~$26.9M). The filing document itself contains no specific share counts, ownership percentages, dollar amounts, or detailed changes — only header information identifying the filer (GMS Ventures, Cayman Islands entity) and the subject company (Outlook Therapeutics, Iselin NJ, biological products). Concrete amendment details are absent from the accessible text.
Why this rating
Routine amended disclosure filing; no material facts disclosed. Without shareholding specifics or transaction details, cannot assess impact magnitude.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.